FDA releases Pfizer after SINCERE patient recruitment challenges
This article was originally published in Scrip
Pfizer has called an end to its SINCERE study designed to collect long-term safety data for Celebrex (celecoxib) in paediatric patients with juvenile idiopathic arthritis (JIA), despite the fact that Celebrex was only granted US FDA approval on the condition that the post-marketing study was conducted.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.